Deficiency of Follistatin-Like Protein 1 Accelerates the Growth of Breast Cancer Cells at Lung Metastatic Sites.
- Author:
Ying ZHANG
1
;
Xiaozhou XU
;
Ying YANG
;
Jie MA
;
Lulu WANG
;
Xiangzhi MENG
;
Bing CHEN
;
Ling QIN
;
Tao LU
;
Yan GAO
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; Follistatin-related proteins; Neoplasm metastasis; Tumor suppressor genes
- MeSH: Animals; Blotting, Western; Breast Neoplasms*; Breast*; Enzyme-Linked Immunosorbent Assay; Eosine Yellowish-(YS); Follistatin-Related Proteins*; Genes, Tumor Suppressor; Glycoproteins; Hematoxylin; Humans; Lung*; Mice; Neoplasm Metastasis; Polymerase Chain Reaction; Receptor, Epidermal Growth Factor; Reverse Transcription; Sequence Analysis, RNA
- From:Journal of Breast Cancer 2018;21(3):267-276
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein that has been shown to play a role in various types of cancer. However, the clinical significance and function of FSTL1 in breast cancer have not been reported. We investigated the role of FSTL1 in breast cancer in this study. METHODS: Enzyme-linked immunosorbent assays, western blot analysis, and reverse transcription polymerase chain reaction were used to monitor the expression of FSTL1 in breast cancer tissue and in serum samples from breast cancer patients. We employed a 4T1 breast cancer model and Fstl1(+/−) mice for in vivo studies. Hematoxylin and eosin staining, western blot analysis, and RNA sequencing were used to analyze the effect of FSTL1 on primary tumor growth and lung metastasis. RESULTS: We demonstrated that the expression of FSTL1 is reduced in both the breast cancer tissue and the serum of breast cancer patients. We showed that reduced levels of FSTL1 in serum correlate with elevated expression of Ki-67 and epidermal growth factor receptor (EGFR) in cancer tissues. Moreover, lowered expression of FSTL1 was associated with decreased survival in breast cancer patients. Experiments on the Fstl1(+/−) mouse model established that FSTL1 deficiency had no effect on primary tumor growth, but increased the lung metastases of breast cancer cells, resulting in reduced survival of tumor-bearing mice. RNA sequencing found significantly reduced expression of Egln3 and increased expression of EGFR in Fstl1(+/−) mice. Thus, our results suggest that FSTL1 may affect the expression of EGFR through Egln3, inhibiting the proliferation of breast cancer cells at lung metastatic sites. CONCLUSION: In conclusion, we suggest a suppressor role of FSTL1 in breast cancer lung metastasis. Furthermore, FSTL1 may represent a potential prognostic biomarker and a candidate therapeutic target in breast cancer patients.
